The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients With Bipolar I Disorder
Abstract
BACKGROUND: The anticonvulsant lamotrigine was previously shown to be effective for bipolar depression. This study assessed the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of mood episodes in bipolar disorder. METHOD: During an 8- to 16-week open-label phase, lamotrigine (titrated to 200 mg/day) was added to current therapy for currently or recently depressed DSM-IV-defined bipolar I outpatients (N = 966) and concomitant drugs were gradually withdrawn. Patients stabilized on open-label treatment (N = 463) were then randomly assigned to lamotrigine (50, 200, or 400 mg/day; N = 221), lithium (0.8-1.1 mEq/L; N = 121), or placebo (N = 121) monotherapy for up to 18 months. The primary outcome measure was time from randomization to intervention (addition of pharmacotherapy) for any mood episode (depressive, manic, hypomanic, or mixed). Data were gathered from September 1997 to August 2001. RESULTS: Time to intervention for any mood episode was statistically superior (p = .029) for both lamotrigine and lithium compared with placebo-median survival times were 200, 170, and 93 days, respectively. Intervention for depression was more frequent than for mania by a factor of nearly 3:1. Lamotrigine was statistically superior to placebo at prolonging the time to intervention for a depressive episode (p = .047). The proportions of patients who were intervention-free for depression at 1 year were lamotrigine 57%, lithium 46%, and placebo 45%. Lithium was statistically superior to placebo at prolonging the time to intervention for a manic or hypomanic episode (p = .026). The proportions of patients who were intervention-free for mania at 1 year were lamotrigine 77%, lithium 86%, and placebo 72%. Headache was the most frequent adverse event for all 3 treatment groups. CONCLUSION: Lamotrigine and lithium were superior to placebo for the prevention of mood episodes in bipolar I patients, with lamotrigine predominantly effective against depression and lithium predominantly effective against mania.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1976) · Medical Entomology and Zoology · Cited by 8,899
A Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Regier, D. A. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820140007001 · Cited by 1,999
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678
Self-citationBowden, C. L. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.4.392 · Cited by 658
Self-citationBaastrup, P. C., Poulsen, J. C., Schou, M., Thomsen, K., & Amdisen, A. (1970) · The Lancet · doi:10.1016/s0140-6736(70)92870-9 · Cited by 505
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationLithium toxicity profile: a systematic review and meta-analysis
McKnight, R. F., Adida, M., Budge, K., Stockton, S., Goodwin, G. M., & Geddes, J. R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61516-x · Cited by 877
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Lamotrigine has greater efficacy in the prevention of depressive relapse but relatively modest impact on risk of manic relapse (Level I) (Bowden et al., 2003; Calabrese et al., 2003; Goodwin et al., 2004; Licht et al., 2010; Van der Loos et al., 2011).”
BackgroundDecreased risk of suicides and attempts during long‐term lithium treatment: a meta‐analytic review
Baldessarini, R. J., Tondo, L., Davis, P., Pompili, M., Goodwin, F. K., & Hennen, J. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00344.x · Cited by 753
Cipriani, A., Pretty, H., Hawton, K., & Geddes, J. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1805 · Cited by 617
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1 · Cited by 583
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559
Self-citationLithium side effects and toxicity: prevalence and management strategies
Gitlin, M. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0068-y · Cited by 531
Tohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., Calabrese, J. R., Nolen, W. A., Vieta, E., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00726.x · Cited by 513
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Self-citationLeverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S. L., Keck, P. E., Kupka, R. W., Denicoff, K. D., Nolen, W. A., Grunze, H., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.232 · Cited by 419
Antidepressants in bipolar disorder: the case for caution
Ghaemi, S. N., Hsu, D. J., Soldani, F., & Goodwin, F. K. (2003) · Bipolar Disorders · doi:10.1046/j.1399-5618.2003.00074.x · Cited by 393
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Self-citationTohen, M., Greil, W., Calabrese, J. R., Sachs, G. S., Yatham, L. N., Oerlinghausen, B. M., Koukopoulos, A., Cassano, G. B., Grunze, H., Licht, R. W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1281 · Cited by 365
Self-citationSuppes, T., Dennehy, E. B., Hirschfeld, R. M. A., Altshuler, L. L., Bowden, C. L., Calabrese, J. R., Crismon, M. L., Ketter, T. A., Sachs, G. S., Swann, A. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0710 · Cited by 330
Self-citationTohen, M., Calabrese, J. R., Sachs, G. S., Banov, M. D., Detke, H. C., Risser, R., Baker, R. W., Chou, J. C.-Y., & Bowden, C. L. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.247 · Cited by 317
“Similar to the procedures used by Calabrese et al. ( 6 ), the attribution of manic, depressed, or mixed episode in patients hospitalized for relapse during the double-blind maintenance phase was made by means of best clinical judgment based on all available information documented in the clinical report form and confir…”
BackgroundMethodSelf-citationCollaborative care for bipolar disorder, Part II: impact on clinical outcome, function, and costs.
Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., & Sajatovic, M. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.7.937 · Cited by 312
Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R., Ketter, T. A., Marangell, L. B., Miklowitz, D. J., Miyahara, S., Bauer, M. S., Thase, M. E., Wisniewski, S. R., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.210 · Cited by 257
Self-citationCalabrese, J. R., Shelton, M. D., Rapport, D. J., Youngstrom, E. A., Jackson, K., Bilali, S., Ganocy, S. J., & Findling, R. L. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2152 · Cited by 252
Self-citationLithium and suicide in mood disorders: Updated meta‐review of the scientific literature
Smith, K. A., & Cipriani, A. (2017) · Bipolar Disorders · doi:10.1111/bdi.12543 · Cited by 247
Vieta, E., Suppes, T., Eggens, I., Persson, I., Paulsson, B., & Brecher, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.001 · Cited by 227
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“…of any polarity or a new manic, depressive or mixed episode Two randomised, placebo and comparator (lithium)controlled studies over 18 months demonstrated the prophylactic efficacy of lamotrigine in BD-I patients, recently (hypo)manic or depressed (Calabrese et al. 2003; Bowden et al. 2003).”
BackgroundInfluentialSelf-citationDivalproex in the treatment of bipolar depression: a placebo-controlled study
Davis, L. L., Bartolucci, A., & Petty, F. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.09.009 · Cited by 181
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00946-6 · Cited by 169
Oquendo, M. A., Galfalvy, H. C., Currier, D., Grunebaum, M. F., Sher, L., Sullivan, G. M., Burke, A. K., Harkavy-Friedman, J., Sublette, M. E., Parsey, R. V., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010163 · Cited by 165
Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview
Dias, V. V., Balanzá‐Martinez, V., Soeiro‐de‐Souza, M. G., Moreno, R. A., Figueira, M. L., Machado‐Vieira, R., & Vieta, E. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01910.x · Cited by 146
Fountoulakis, K. N., Tohen, M., & Zarate, C. A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.003 · Cited by 146
Quality of life in patients with bipolar I depression: data from 920 patients
Yatham, L. N., Lecrubier, Y., Fieve, R. R., Davis, K. H., Harris, S. D., & Krishnan, A. A. (2004) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00134.x · Cited by 142
Self-citationBond, D. J., Lam, R. W., & Yatham, L. N. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.11.008 · Cited by 122
Self-citationVázquez, G. H., Holtzman, J. N., Lolich, M., Ketter, T. A., & Baldessarini, R. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.013 · Cited by 102
“…to lithium or valproate) to 66.7% (with valproate alone; Table 2; Quitkin et al., 1981; Prien et al., 1984; Greil et al., 1997; Bowden et al., 2003; Calabrese et al., 2003; Hartong et al., 2003; Tohen et al., 2004; Findling et al.; 2005; Keck et al., 2007; Vieta et al., 2008; Suppes et al.,…”
InfluentialMaintenance Treatment Outcomes in Older Patients with Bipolar I Disorder
Sajatovic, M., Gyulai, L., Calabrese, J. R., Thompson, T. R., Wilson, B. G., White, R., & Evoniuk, G. (2005) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200504000-00006 · Cited by 93
Self-citationPolytherapy in Bipolar Disorder
Lin, D., Mok, H., & Yatham, L. N. (2006) · CNS Drugs · doi:10.2165/00023210-200620010-00003 · Cited by 91
Self-citationAustralian and New Zealand clinical practice guidelines for the treatment of bipolar disorder
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder (2004) · Australian and New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2004.01356.x · Cited by 90
Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
Bipolar depression: issues in diagnosis and treatment
Thase, M. E. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220500326425 · Cited by 89
Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder
Fountoulakis, K. N., Vieta, E., Siamouli, M., Valenti, M., Magiria, S., Oral, T., Fresno, D., Giannakopoulos, P., & Kaprinis, G. S. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-27 · Cited by 76
“mania [45,86-93].”
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
Brown, E., Dunner, D. L., McElroy, S. L., Keck, P. E., Adams, D. H., Degenhardt, E., Tohen, M., & Houston, J. P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009735 · Cited by 73
Nolen, W. A., & Weisler, R. H. (2013) · Bipolar Disorders · doi:10.1111/bdi.12027 · Cited by 73
The pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69
“One hierarchy of mood stabilizer options is: (i) lithium carbonate; (ii) divalproex; (iii) olanzapine (now FDA-approved for mania and maintenance in bipolar disorder); and (iv) lamotrigine (FDA-approved for maintenance in bipolar disorder).(95,97,98) The particular medication is chosen on the basis of the patient’s hi…”
BackgroundCarlson, B. X., Ketter, T. A., Sun, W., Timko, K., McQuade, R. D., Sanchez, R., Vester‐Blokland, E., & Marcus, R. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00974.x · Cited by 63
Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications
Brugue, E., & Vieta, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.014 · Cited by 54
Lamotrigine Use in Geriatric Patients with Bipolar Depression
Robillard, M., & Conn, D. K. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700808 · Cited by 45
Kemp, D. E., Gao, K., Fein, E. B., Chan, P. K., Conroy, C., Obral, S., Ganocy, S. J., & Calabrese, J. R. (2012) · Bipolar Disorders · doi:10.1111/bdi.12013 · Cited by 39
Self-citationLamotrigine plus Quetiapine Combination Therapy in Treatment-Resistant Bipolar Depression
Ahn, Y. M., Nam, J. Y., Culver, J. L., Marsh, W. K., Bonner, J. C., & Ketter, T. A. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300104 · Cited by 23
Grunze, H., Kotlik, E., Costa, R., Nunes, T., Falcão, A., Almeida, L., & Soares-da-Silva, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.013 · Cited by 22
Muck-Seler, D., Sagud, M., Mustapic, M., Nedic, G., Babic, A., Mihaljevic Peles, A., Jakovljevic, M., & Pivac, N. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.03.004 · Cited by 21
A factor analytic study in bipolar depression, and response to lamotrigine
Mitchell, P. B., Hadzi-Pavlovic, D., Evoniuk, G., Calabrese, J. R., & Bowden, C. L. (2013) · CNS Spectrums · doi:10.1017/s1092852913000291 · Cited by 20
Self-citationKumar, R., Nuñez, N. A., Prokop, L. J., Veldic, M., Betcher, H., & Singh, B. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001475 · Cited by 16
Pharmacological treatment of mixed states
Cuomo, A., Nikolova, V. L., Yalin, N., Arnone, D., Fagiolini, A., & Young, A. H. (2017) · CNS Spectrums · doi:10.1017/s1092852917000013 · Cited by 14
Adjunctive use of modafinil in bipolar patients: just another stimulant or not?
Shelton, R. C., & Reddy, R. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0082-6 · Cited by 11
Pan, P.-Y., Lee, M.-S., Lo, M.-C., Yang, E.-L., & Yeh, C.-B. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-145 · Cited by 9
Metadata
- Authors
- Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Ascher, J., Paska, W., Earl, N., DeVeaugh-Geiss, J., & Lamictal 605 Study Group
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-09-15
- Volume
- 64
- Issue
- 9
- Pages
- 1013-1024
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2084399232
- Cited by
- 635
- References
- 23
- FWCI
- 33.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.